C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis

Ren, Jing; Wang, Hui; Wang, Wen J; Hu, Gui M; Gu, Bin; Zhang, Min; Wang, Yu X

doi:10.23736/s0031-0808.16.03228-6

Cited by 11 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In concert with our finding, Szturz and collaborators showed an association between a high c-MET expression and worse DSS, progression-free survival, and OS in their systematic review and meta-analysis of 2019 cases of squamous cell carcinoma of the head and neck [ 27 ], which is biologically somewhat related to PeCa [ 28 ]. Similarly, Ren and co-authors reported shorter DSS and OS in patients with c-MET overexpression in squamous cell carcinoma and adenocarcinoma of the esophagus [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

Thomas¹,

Slade²,

Blaheta³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

Thomas¹,

Slade²,

Blaheta³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Transcriptional alterations can involve the receptor or the ligand. MET overexpression is a frequent event in cancer [ 32 , 33 ] and is associated with poor prognosis [ 34 , 35 , 36 , 37 , 38 , 39 ]. It occurs as a mechanism to overcome stress events and bypass barriers during cancer progression [ 40 ].…”

Section: Introductionmentioning

confidence: 99%

MET Oncogene Targeting for Cancer Immunotherapy

Lombardi,

Sangiolo,

Vigna

2024

IJMS

View full text Add to dashboard Cite

The MET receptor is one of the main drivers of ‘invasive growth’, a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expression as a hallmark of transformation. Considering the great interest gained by cancer immunotherapy, this review evaluates the opportunity of targeting MET within therapeutic approaches based on the exploitation of immune functions, either in those cases where MET impairment is crucial to induce an effective response (i.e., when MET is the driver of the malignancy), or when blocking MET represents a way for potentiating the treatment (i.e., when MET is an adjuvant of tumor fitness).

show abstract

Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes

Liang

Wang

Xiao

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis

Cited by 11 publications

References 0 publications

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

MET Oncogene Targeting for Cancer Immunotherapy

Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes

Contact Info

Product

Resources

About